Scholarlink

Purpose <p>Endocrine therapy (ET) can be used as a definitive treatment in frail and elderly breast cancer patients who are unwilling or deemed unfit to undergo surgical treatment. This study evaluated the clinical response to ET as primary treatment in elderly patients with non-metastatic, oestrogen receptor (ER) positive breast cancer, by evaluating its effectiveness over time.</p> Methods <p>Elderly patients (≥ 70&#xa0;years) with ER-positive breast cancer who had been treated with ET as primary treatment between 2008 and 2015 in two Dutch hospitals were identified through the Netherlands Cancer Registry. The primary outcome was the objectively measured clinical response at various time intervals after initiation of ET.</p> Results <p>Out of 122 patients (median age, 86&#xa0;years), 100 (82%) received ET as definitive treatment, whereas 22 (18%) received ET as neo-adjuvant endocrine therapy. Over the 3-year observation period, 25% of patients had died and 29% underwent invasive local treatment. The overall response rate after 3&#xa0;years was 14% for all 122 patients and 30% for the 56 patients who were still alive and had not undergone local treatment after 3&#xa0;years.</p> Conclusion <p>The observed clinical response to ET in a consistent proportion of patients over time suggests it may be a viable option for a selection of frail and elderly breast cancer patients with limited life expectancy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluating clinical response to primary endocrine therapy in elderly breast cancer patients in routine practice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月12日

查看全文
  • Tessa L. Dinger,
  • José H. Volders,
  • Anne Kuijer,
  • Johannes C. Kelder,
  • Annemiek Doeksen,
  • Emily L. Postma,
  • Thijs van Dalen

摘要

Purpose

Endocrine therapy (ET) can be used as a definitive treatment in frail and elderly breast cancer patients who are unwilling or deemed unfit to undergo surgical treatment. This study evaluated the clinical response to ET as primary treatment in elderly patients with non-metastatic, oestrogen receptor (ER) positive breast cancer, by evaluating its effectiveness over time.

Methods

Elderly patients (≥ 70 years) with ER-positive breast cancer who had been treated with ET as primary treatment between 2008 and 2015 in two Dutch hospitals were identified through the Netherlands Cancer Registry. The primary outcome was the objectively measured clinical response at various time intervals after initiation of ET.

Results

Out of 122 patients (median age, 86 years), 100 (82%) received ET as definitive treatment, whereas 22 (18%) received ET as neo-adjuvant endocrine therapy. Over the 3-year observation period, 25% of patients had died and 29% underwent invasive local treatment. The overall response rate after 3 years was 14% for all 122 patients and 30% for the 56 patients who were still alive and had not undergone local treatment after 3 years.

Conclusion

The observed clinical response to ET in a consistent proportion of patients over time suggests it may be a viable option for a selection of frail and elderly breast cancer patients with limited life expectancy.